Genmab | GEN - Current Liabilities

Stock Price
1,706.00
Daily Change
3.50 0.21%
Monthly
-12.67%
Yearly
21.90%
Q1 Forecast
1,614.31

Genmab reported DKK629M in Current Liabilities for its fiscal quarter ending in June of 2025.





Current Liabilities Change Date
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Almirall EUR 350.64M 52.12M Dec/2025
Amarin USD 182.23M 3.71M Sep/2025
Amgen USD 25.49B 3.7B Dec/2025
argenx SE USD 1.04B 371.99M Jun/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
Bayer EUR 32.58B 3.63B Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Demant DKK 7.42B 1.63B Dec/2025
Exelixis USD 405.64M 31.86M Dec/2025
Fresenius Medical Care EUR 6.25B 485.68M Dec/2025
Galapagos EUR 152.86M 213.7M Dec/2025
Genmab DKK 629M 127M Jun/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
GN Store Nord DKK 7.32B 153M Dec/2025
GRIFOLS EUR 2.02B 135.85M Dec/2025
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
Lonza CHF 3.58B 970M Dec/2024
Merck EUR 9.04B 405M Dec/2025
Novartis USD 32B 286M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
Sanofi EUR 28.35B 3.76B Dec/2025
UCB EUR 3.53B 731M Dec/2024